Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Oncology Specialties, P.C.

Neither a doctor nor a teaching hospital

Research payments

$216,697

41 payments

Through program year 2025, Oncology Specialties, P.C. is reported as receiving $216,697 in research payments, across 41 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $175 1
2024 Research $17,500 3
2023 Research $70,135 5
2022 Research $18,082 8
2021 Research $66,706 6
2020 Research $750 1
2019 Research $43,349 17

Breakdown

Who paid Research payments · program years 2019–2025
  1. BeiGene, Ltd. $120,224 5 payments
  2. AbbVie, Inc. $42,249 16 payments
  3. Sobi, Inc $17,500 3 payments
  4. Incyte Corporation $14,047 9 payments
  5. MorphoSys AG $11,577 5 payments
  6. Ipsen Bioscience Inc $10,000 2 payments
  7. AstraZeneca Pharmaceuticals LP $1,100 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib $63,074 3 payments
  2. A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib $57,150 2 payments
  3. M16-289 $29,820 7 payments
  4. Real-World Treatment Patterns and Outcomes in Patients With Immune Thrombocytopenic Purpura Treated With Avatrombopag in the United States $17,500 3 payments
  5. M16-298 $12,429 9 payments
  6. realMIND: Observational Study of Patients With Relapsed or Refractory DLBCL Starting Second- or Third-line Therapy (realMIND) $10,976 4 payments
  7. An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas $10,000 2 payments
  8. Prospective, Longitudinal, Non Interventional Study of Disease Burden and Treatment of Patients With Low Risk Myelofibrosis (MF) Or High Risk Essential Thrombocythemia (Et) Or Et Patients Receiving Et Directed Therapy $7,412 7 payments
  9. Prospective, Longitudinal, Non Interventional Study of Disease Burden and Treatment of Patients With Low Risk Myelofibrosis (MF) Or High Risk Essential Thrombocythemia (Et) Or Et Patients Receiving Et Directed Therapy $6,460 1 payment
  10. IRESSA US Clinical Access Program CAP $1,100 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record